VolitionRx Limited (NYSE AMERICAN: VNRX) reported $1 million in first-quarter 2026 revenue, marking a 300% increase from the prior year period, according to a company statement.

The Henderson, Nevada-based epigenetics company submitted a clinical manuscript for its Nu.Q Vet cancer test in cats, which could trigger a $5 million milestone payment upon publication. The test demonstrated 86% detection of feline lymphomas with 97% specificity in clinical studies.

VolitionRx said it has active licensing discussions with more than a dozen diagnostic and liquid biopsy companies. The company submitted a paper for peer review on its Capture-Seq platform, which detected over 95% of Stage I and II cancers in a validation cohort.

The company's Nu.Q NETs assay was included in France's $7.3 million government-backed DETECSEPS sepsis detection program, scheduled to begin in the third quarter of 2026. VolitionRx also announced successful detection of nucleosomes in capillary blood from sepsis patients using a lateral flow prototype test.

The company submitted a reimbursement application in France for its Nu.Q Cancer assays, with routine clinical use expected by the end of 2026. The submission is supported by Hospices Civils de Lyon, France's second largest university hospital system.

VolitionRx estimates its total addressable markets at $27+ billion annually across cancer detection ($23 billion), sepsis testing ($3.8 billion), and veterinary applications ($1+ billion). The Nu.Q Vet Canine test is currently available in more than 20 countries.